Leveraging diversity within the CHOK1SV pool can identify new host cell lines with different performance characteristics for recombinant protein production.
Answers are grounded in this paper and cite their sources.
Cell line variation in CHOK1SV advises screening multiple clones for biologics production; leaves open whether ER mass reliably predicts yield across platforms.
Much effort has been expended to improve the capabilities of individual Chinese hamster ovary (CHO) host cell lines to synthesize recombinant therapeutic proteins (rPs). However, given the increasing variety in rP molecular types and formats it may be advantageous to employ a toolbox of CHO host cell lines in biomanufacturing. Such a toolbox would contain a panel of hosts with specific capabilities to synthesize certain molecular types at high volumetric concentrations and with the correct product quality (PQ). In this work, we examine a panel of clonally derived host cell lines isolated from CHOK1SV for the ability to manufacture two model proteins, an IgG4 monoclonal antibody (Mab) and an Fc-fusion protein (etanercept). We show that these host cell lines vary in their relative ability to synthesize these proteins in transient and stable pool production format. Furthermore, we examined the PQ attributes of the stable pool-produced Mab and etanercept (by N-glycan ultra performance liquid chromatography (UPLC) and liquid chromatography - tandem mass spectrometry (LC-MS/MS), respectively), and uncovered substantial variation between the host cell lines in Mab N-glycan micro-heterogeneity and etanercept N and O-linked macro-heterogeneity. To further investigate the capabilities of these hosts to act as cell factories, we examined the glycosylation pathway gene expression profiles as well as the levels of endoplasmic reticulum (ER) and mitochondria in the untransfected hosts. We uncovered a moderate correlation between ER mass and the volumetric product concentration in transient and stable pool Mab production. This work demonstrates the utility of leveraging diversity within the CHOK1SV pool to identify new host cell lines with different performance characteristics.
No takes yet. Share an insight, caveat, or question.
O’Callaghan et al. (2015) studied Biomanufacturing of recombinant therapeutic proteins. Clonally derived host cell lines isolated from CHOK1SV was evaluated on Ability to manufacture two model proteins (IgG4 Mab and etanercept) and product quality attributes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: